Penserra Capital Management LLC Zynerba Pharmaceuticals, Inc. Transaction History

Penserra Capital Management LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.3 - $0.43 $513 - $736	1,712 Added 0.78%	220,858 $71,000
Q1 2023 Apr 24, 2023	BUY	$0.4 - $0.67 $1,369 - $2,294	3,424 Added 1.59%	219,146 $94,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $0.72 $1,712 - $2,465	3,424 Added 1.61%	215,722 $114,000
Q3 2022 Nov 14, 2022	SELL	$0.87 - $1.36 $119,223 - $186,371	-137,038 Reduced 39.23%	212,298 $155,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $2.06 $1,563 - $3,745	-1,818 Reduced 0.52%	349,336 $398,000
Q1 2022 May 13, 2022	SELL	$1.83 - $3.02 $107,801 - $177,902	-58,908 Reduced 14.37%	351,154 $719,000
Q4 2021 Feb 15, 2022	BUY	$2.88 - $4.3 $84,568 - $126,265	29,364 Added 7.71%	410,062 $1.18 Million
Q3 2021 Nov 15, 2021	BUY	$3.72 - $5.35 $30,928 - $44,479	8,314 Added 2.23%	380,698 $1.61 Million
Q2 2021 Aug 12, 2021	BUY	$3.83 - $5.98 $59,395 - $92,737	15,508 Added 4.35%	372,384 $1.97 Million
Q1 2021 May 13, 2021	BUY	$3.33 - $8.76 $757,987 - $1.99 Million	227,624 Added 176.11%	356,876 $1.66 Million
Q4 2020 Feb 12, 2021	BUY	$3.27 - $4.64 $210,097 - $298,120	64,250 Added 98.84%	129,252 $425,000
Q3 2020 Nov 13, 2020	SELL	$3.23 - $4.3 $96,770 - $128,828	-29,960 Reduced 31.55%	65,002 $214,000
Q2 2020 Aug 14, 2020	BUY	$3.31 - $6.54 $23,236 - $45,910	7,020 Added 7.98%	94,962 $319,000
Q1 2020 May 14, 2020	BUY	$2.9 - $6.16 $182,160 - $386,934	62,814 Added 249.98%	87,942 $336,000
Q4 2019 Feb 14, 2020	BUY	$5.61 - $8.57 $35,915 - $54,865	6,402 Added 34.19%	25,128 $125,000
Q3 2019 Nov 15, 2019	BUY	$7.56 - $15.44 $141,568 - $289,129	18,726 New	18,726 $141,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.